Fresenius Kabi announced the launch of Smoflipid, a parenteral nutrition product, for use in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. The company initially received approval from the Food and Drug Administration in July 2016.

Smoflipid is the first intravenous fat emulsion product to contain four oils: 30% soybean oil, 30% medium chain triglycerides (MCT), 25% olive oil, and 15% fish oil. It increases heat production, decreases respiratory quotient, and increases oxygen consumption following its administration. 

Related Articles

Smoflipid is supplied as a lipid injectable emulsion with a lipid content of 0.2g/mL in 100mL and 250mL bags in 10-count boxes, and as a 500mL bag in 12-count boxes.

For more information call (800) 551-7176 or visit